NICHOLE WISE: Open Payments
NPI 1225654189 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$601 in 26 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $601
Food & beverage: $601
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $112 |
| Madrigal Pharmaceuticals | 4 | $89 |
| Ardelyx, Inc. | 4 | $64 |
| Janssen Biotech, Inc. | 1 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| GENZYME CORPORATION | 1 | $39 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Celltrion USA Inc. | 1 | $22 |
Products named: ENTYVIO, REZDIFFRA, DUPIXENT, IBSRELA, TREMFYA, XIFAXAN, IQIRVO, VOQUEZNA.
Industry payments across IN — which companies pay providers there.
